Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors
Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors
HAUPPAUGE, N.Y., Dec. 17, 2020 Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company’s Board of Directors.
“We are pleased to welcome David to our Board of Directors. He adds directly applicable expertise in public health and infectious disease management to our leadership team, and we are confident his perspective will contribute meaningfully to our long-term value creation strategy,” said Katherine L. Davis, Chair of Chembio’s Board of Directors. “We look forward to his leadership and insights as we enter the next phase of growth for Chembio.”